Travere Therapeutics (TVTX) Change in Acquisitions & Divestments (2013 - 2026)

Travere Therapeutics (TVTX) has 14 years of Change in Acquisitions & Divestments data on file, last reported at $48.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 8.23% year-over-year to $48.8 million; the trailing twelve-month figure through Mar 2026 stood at $319.2 million (up 19.06% YoY), and the FY2025 full-year result was $323.6 million, down 0.84% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $48.8 million, down from $82.4 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $152.6 million in Q2 2022 and bottomed at $48.8 million in Q1 2026.
• The 5-year median for Change in Acquisitions & Divestments is $82.4 million (2025), against an average of $83.3 million.
• The widest annual swing landed in 2022, when Change in Acquisitions & Divestments plunged 57.54%; it then soared 96.29% in 2025.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $52.4 million in 2022, then decreased by 4.55% to $50.0 million in 2023, then rose by 10.1% to $55.0 million in 2024, then soared by 49.72% to $82.4 million in 2025, then sank by 40.81% to $48.8 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $48.8 million (Q1 2026), $82.4 million (Q4 2025), and $106.6 million (Q3 2025), per Business Quant data.

Peer Comparison